Improving TCR Gene Therapy for Treatment of Haematological Malignancies
Adoptive immunotherapy using TCR gene modified T cells may allow separation of beneficial Graft versus tumour responses from harmful GvHD. Improvements to this include methods to generate high avidity or high affinity TCR, improvements in vector design and reduction in mispairing. Following adoptive...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Advances in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2012/404081 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832566375714914304 |
|---|---|
| author | Emma Nicholson Sara Ghorashian Hans Stauss |
| author_facet | Emma Nicholson Sara Ghorashian Hans Stauss |
| author_sort | Emma Nicholson |
| collection | DOAJ |
| description | Adoptive immunotherapy using TCR gene modified T cells may allow separation of beneficial Graft versus tumour responses from harmful GvHD. Improvements to this include methods to generate high avidity or high affinity TCR, improvements in vector design and reduction in mispairing. Following adoptive transfer, TCR transduced T cells must be able to survive and persist in vivo to give most effective antitumour responses. Central memory or naive T cells have both been shown to be more effective than effector cells at expanding and persisting in vivo. Lymphodepletion may enhance persistence of transferred T cell populations. TCR gene transfer can be used to redirect CD4 helper T cells, and these could be used in combination with CD8+ tumour specific T cells to provide help for the antitumour response. Antigen specific T regulatory T cells can also be generated by TCR gene transfer and could be used to suppress unwanted alloresponses. |
| format | Article |
| id | doaj-art-ea8270d6a2c8448eb1dbafdbbefc859e |
| institution | Kabale University |
| issn | 1687-9104 1687-9112 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advances in Hematology |
| spelling | doaj-art-ea8270d6a2c8448eb1dbafdbbefc859e2025-02-03T01:04:26ZengWileyAdvances in Hematology1687-91041687-91122012-01-01201210.1155/2012/404081404081Improving TCR Gene Therapy for Treatment of Haematological MalignanciesEmma Nicholson0Sara Ghorashian1Hans Stauss2Department of Immunology, Royal Free Hospital, University College London, Hampstead Campus, Rowland Hill Street, London NW3 2QG3, UKDepartment of Immunology, Royal Free Hospital, University College London, Hampstead Campus, Rowland Hill Street, London NW3 2QG3, UKDepartment of Immunology, Royal Free Hospital, University College London, Hampstead Campus, Rowland Hill Street, London NW3 2QG3, UKAdoptive immunotherapy using TCR gene modified T cells may allow separation of beneficial Graft versus tumour responses from harmful GvHD. Improvements to this include methods to generate high avidity or high affinity TCR, improvements in vector design and reduction in mispairing. Following adoptive transfer, TCR transduced T cells must be able to survive and persist in vivo to give most effective antitumour responses. Central memory or naive T cells have both been shown to be more effective than effector cells at expanding and persisting in vivo. Lymphodepletion may enhance persistence of transferred T cell populations. TCR gene transfer can be used to redirect CD4 helper T cells, and these could be used in combination with CD8+ tumour specific T cells to provide help for the antitumour response. Antigen specific T regulatory T cells can also be generated by TCR gene transfer and could be used to suppress unwanted alloresponses.http://dx.doi.org/10.1155/2012/404081 |
| spellingShingle | Emma Nicholson Sara Ghorashian Hans Stauss Improving TCR Gene Therapy for Treatment of Haematological Malignancies Advances in Hematology |
| title | Improving TCR Gene Therapy for Treatment of Haematological Malignancies |
| title_full | Improving TCR Gene Therapy for Treatment of Haematological Malignancies |
| title_fullStr | Improving TCR Gene Therapy for Treatment of Haematological Malignancies |
| title_full_unstemmed | Improving TCR Gene Therapy for Treatment of Haematological Malignancies |
| title_short | Improving TCR Gene Therapy for Treatment of Haematological Malignancies |
| title_sort | improving tcr gene therapy for treatment of haematological malignancies |
| url | http://dx.doi.org/10.1155/2012/404081 |
| work_keys_str_mv | AT emmanicholson improvingtcrgenetherapyfortreatmentofhaematologicalmalignancies AT saraghorashian improvingtcrgenetherapyfortreatmentofhaematologicalmalignancies AT hansstauss improvingtcrgenetherapyfortreatmentofhaematologicalmalignancies |